Related Experiment Video

Updated: Mar 24, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.7K

Optimization of Triptorelin Administration in Children With Central Precocious Puberty and Short Stature

Hai-Bo Yao1, Hong-Xia Xie1, He-Ping Fan1

  • 1Department of Pediatrics, Sinopharm Tongmei General Hospital, Datong, Shanxi, China.

Clinical Endocrinology
|March 17, 2026
PubMed

Insights

Triptorelin treatment effectively improves height in children with central precocious puberty (CPP) and short stature. Individualized therapy combining triptorelin and growth hormone (GH) maximizes height potential, with flexible dosing based on pubertal suppression.

Area of Science:

  • Pediatric Endocrinology
  • Reproductive Medicine
  • Growth Disorders

Background:

  • Central precocious puberty (CPP) involves early onset of puberty, leading to potential height deficits.
  • Short stature in children can be exacerbated by premature puberty.
  • Triptorelin is a gonadotropin-releasing hormone (GnRH) agonist used to suppress puberty.

Purpose of the Study:

  • To investigate the individualized use of triptorelin in children with CPP and short stature.
  • To analyze treatment protocols, monitoring, and outcomes related to predicted adult height (PHA).

Main Methods:

  • Retrospective analysis of 26 children with CPP and short stature treated with triptorelin from June 2018 to May 2022.
  • Evaluation of treatment purposes, indications, protocols, and changes in PHA.
  • Comparison of triptorelin monotherapy versus combination therapy with growth hormone (GH).

Main Results:

  • 24 of 26 children received triptorelin primarily for height improvement.
  • Significant improvements in PHA were observed after 1 year of treatment in children receiving triptorelin and GH combination therapy.
  • Bone age varied among participants, with some cases showing advanced bone age, including one with congenital adrenal hyperplasia (CAH).

Conclusions:

  • Triptorelin is effective for CPP and short stature associated with premature sexual development.
  • Individualized triptorelin-GH combination therapy offers superior height outcomes.
  • Treatment protocols, including dosing intervals and timing, should be carefully considered for optimal results.
Abstract

Keywords:
central precocious puberty (CPP)heightindividualized treatmentshort staturetriptorelin

More Related Videos

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues10:36

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues

Published on: March 21, 2017

8.1K
A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

10.6K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
369
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
322
Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
73
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
720
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.2K
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
443